8B-2 Imaging of Iron Oxide Nanoparticles Using Magneto-Motive Ultrasound
暂无分享,去创建一个
S. Park | S. Mallidi | S. Emelianov | K. Sokolov | S. Mallidi | K. Johnston | M. Mehrmohammadi | T. Larson | S. Emelianov | E. Yantsen | S. Park | E. Yantsen | T. Larson | K. Sokolov | M. Mehrmohammadi | J. Oh | L. Ma | K.P. Johnston | T. Miner | T. Miner | J. Oh | L. Ma
[1] Michel Claudon,et al. Ultrasound contrast agents: properties, principles of action, tolerance, and artifacts , 2001, European Radiology.
[2] R M Peshock,et al. Administration of an intravenous perfluorocarbon contrast agent improves echocardiographic determination of left ventricular volumes and ejection fraction: comparison with cine magnetic resonance imaging. , 1998, Journal of the American College of Cardiology.
[3] V. R. McCready,et al. Microbubble contrast agent for color Doppler US: effect on breast masses. Work in progress. , 1996, Radiology.
[4] Stanislav Emelianov,et al. Molecular specific optoacoustic imaging with plasmonic nanoparticles. , 2007, Optics express.
[5] A. Lu,et al. Magnetic nanoparticles: synthesis, protection, functionalization, and application. , 2007, Angewandte Chemie.
[6] S. Emelianov,et al. Detection of magnetic nanoparticles in tissue using magneto-motive ultrasound , 2006, Nanotechnology.
[7] R Weissleder,et al. Monocrystalline iron oxide nanocompounds (MION): Physicochemical properties , 1993, Magnetic resonance in medicine.
[8] J. Schenck. Safety of Strong, Static Magnetic Fields , 2000, Journal of magnetic resonance imaging : JMRI.